この記事を読む

アテゾリズマブにbeyond PD効果はあるか

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Gandara D…

この記事を読む

免疫療法の性差のその後

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Sys…

この記事を読む

中枢型肺腺癌では骨転移が多く予後不良

New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter coh…

この記事を読む

細胞診スメアでもPD-L1高発現は診断可能

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced …

この記事を読む

オシメルチニブの肺毒性、日本人は特に多い

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian…

この記事を読む

いわゆるオリゴメタに対する局所治療~傾向スコア研究

Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 pat…

この記事を読む

オリゴメタの同定にはPET/CTがよい

Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients…

この記事を読む

ゲノム医療の恩恵を受けられるのはまだまだ少ない

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. Marquart J et al. JAMA …

この記事を読む

TP53変異の共存はALK陽性肺癌の予後に影響する

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Kron A et al …

この記事を読む

術後肺癌の予後スコア化、TNM+他因子でより層別化可能?

Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The developme…